Full-Time

Associate Director Biostatistics

Biostatistics

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$169.2k - $253k/yr

+ Incentive opportunity

Rockville, MD, USA + 1 more

More locations: Princeton, NJ, USA

Hybrid

Hybrid work policy with 20% travel expected; remote arrangements may also be considered.

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
SAS
R
Word/Pages/Docs
Biostatistics
Data Analysis
Excel/Numbers/Sheets
Microsoft Outlook

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • A PhD or Master’s degree in Statistics or Biostatistics is required.
  • A minimum of 7 years of pharmaceutical industry experience is required for PhD holders, or 9 years for Master’s degree holders.
  • Understand the company's products, the competition, and the pharmaceutical industry in general.
  • Demonstrate competent knowledge of the company's work tools, processes, and policies.
  • Maintain current awareness of new drug developments and statistical methodologies in the business.
  • Demonstrate experience leading Phase 1 and early-phase clinical studies, including first-in-human, dose-escalation, dose-expansion, and proof-of-concept trials.
  • Have strong working knowledge of applicable United States regulatory requirements relevant to clinical trial design, analysis, and reporting.
  • Demonstrate the ability to partner effectively with Clinical Development, Clinical Pharmacology, Translational Medicine, Regulatory Affairs, and other key stakeholders.
  • Have experience working within matrixed, multidisciplinary drug development teams.
  • Demonstrate the ability to influence decisions in a matrix environment without direct authority.
  • Demonstrate the ability to support and champion novel statistical approaches that improve decision-making when working with limited or variable early-phase clinical data.
  • Communicate complex statistical concepts and insights clearly to technical and non-technical audiences.
  • Have in-depth knowledge of statistical principles and applications, and experience with SAS and R programming software.
  • Have strong computer skills, including demonstrated experience with Microsoft Word, Excel, PowerPoint, and Outlook.
  • Know how and when to apply organizational policy or procedures to a variety of situations.
  • Manage multiple programs and competing priorities.
Responsibilities
  • Provide strategic statistical leadership for early development programs, including first-in-human, Phase 1, Phase 1b/2a, and proof-of-concept studies.
  • Lead statistical input into study design, protocol development, analysis planning, interpretation, and reporting of early-phase clinical trials.
  • Develop innovative statistical strategies to address key development questions related to safety, dose selection, proof-of-concept, and go/no-go decisions.
  • Serve as the lead statistician for one or more assets and represent Biostatistics on cross-functional asset teams.
  • Partner closely with Clinical Development, Clinical Pharmacology, Clinical Management, Regulatory Affairs, Data Management, and Statistical Programming.
  • Drive evidence-based decision-making through integration of safety, efficacy, pharmacokinetic/pharmacodynamic, biomarker, and translational data.
  • Support key development milestones, including proof-of-concept evaluations, dose selection, and development planning.
  • Influence program strategy by assessing development risks and recommending statistically sound approaches to maximize probability of success.
  • Serve as the Biometrics Trial Lead in the project team and provide expertise and input regarding statistical analysis, tables/listings/figures format, data collection and quality, and the overall timeline.
  • Manage, mentor, and develop biostatisticians, fostering technical excellence.
Desired Qualifications
  • Experience in the central nervous system area.
  • Experience with early-phase clinical trials, preferably first-in-human or pharmacokinetic/pharmacodynamic or biomarker-focused studies.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT’s July 2026 VISIONARY data showed two-year eGFR stabilization and kidney-failure risk reduction.
  • SIMTRIYO cleared FDA review on July 24, 2026, opening a large ADHD market.
  • Japan covered Paradise renal denervation on March 1, 2026, accelerating cardiovascular device revenue.

What critics are saying

  • VOYXACT remains accelerated-approval dependent until the FDA accepts its confirmatory 2026 traditional filing.
  • SIMTRIYO cannot launch until DEA scheduling, delaying cash collection and ceding early prescriptions.
  • Otsuka still depends on a few launches; VOYXACT failure or Simtriyo slowdown would crush growth.

What makes Otsuka Pharmaceutical unique

  • SIMTRIYO became Otsuka’s first U.S. ADHD launch, expanding its CNS franchise on July 24, 2026.
  • VOYXACT gave Otsuka first U.S. APRIL inhibition and traditional-approval runway in IgAN.
  • Astex’s fragment-based platform secured Genentech’s breast-cancer pact on July 6, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.